Bacterial infections in the elderly patient: Focus on sitafloxacin

Clinical Medicine Insights: Therapeutics

Volumn 4, Issue , 2012, Pages 185-200

  Ghebremedhin, Beniam ^a  

^a University Clinic Magdeburg   (Germany)

Author keywords

DU 6859a; Fluoroquinolone; MDR organisms; Respiratory and urogenital infections; Sitafloxacin

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; ENOXACIN; ETHAMBUTOL; FLUCONAZOLE; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; SITAFLOXACIN; SPARFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN;

ABNORMAL LABORATORY RESULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; LEUKOCYTE; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PHARMACODYNAMICS; PHOTOTOXICITY; PNEUMONIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUPERINFECTION; TOOTH INFECTION; TREATMENT OUTCOME; TUBERCULOSIS; URETHRITIS; URINARY TRACT INFECTION; UTERINE CERVICITIS;

EID: 84864618691     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S7435     Document Type: Review

References (133)

1. Miller RA. The aging immune system: Primer and prospectus. Science. 1996;273:70-4.
2. Stump TE, Callahan CM, Hendrie HC. Cognitive impairment and mortality in older primary care patients. J Am Geriatr Soc. 2001;49:934-40.
3. Sansoni P, Vescovini R, Fagnoni F, Biasini C, et al. The immune system in extreme longevity. Exp Gerontol. 2008;43(2):61-5.
4. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician. 2001;63(2):257-68.
5. Xie C, Taylor DM, Howden BP, Charles PG. Comparison of the bacterial isolates and antibiotic resistance patterns of elderly nursing home and general community patients. Intern Med J. Jan 17, 2011.
6. Albertson TE, Louie S, Chan AL. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J Am Geriatr Soc. 2010;58(3):570-9.
7. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009;64:i3-10.
8. Livermore DM. British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother. 2011;66(9):1941-4.
9. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41 Suppl 2:S144-57.
10. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007;41(11):1859-66.
11. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drug. 2002;62(1):13-59.
12. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-Naphthyridine derivates. A new class of chemotherapeutic agents. J Med Pharm Chem. 1962;91:1063-5.
13. McChesney EW, Froehlich EJ, Lesher GY, Crain AV, Rosi D. Absorption, excretion, and metabolism of a new antibacterial agent, nalidixic acid. Toxicol Appl Pharmacol. 1964;6:292-309.
14. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16(1):5-15.
15. Dollery C. Therapeutic Drugs. Antibiotic Metabolite of Nalidixic acid, 2nd ed. Churchill Livingstone; 1999.
16. Yokota S, Sato K, Kuwahara O, et al. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antmicrob Agents Chemother. 2002;46(10):3311-5.
17. Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother. 2003;52(6):944-52.
18. Wispelwey B, Schafer KR. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Rev Anti Infect Ther. 2010;8(11):1259-71.
19. Keating GM. Sitafloxacin: in bacterial infections. Drugs. 2011;71(6):731-44.
20. Poirel L, Cattoir V, Nordmann P. Plasmid-mediated quinolone resistance; interactions between human, animal, and environmental ecologies. Front Microbiol. 2012;3:24.
21. Koga H, Itoh A, Murayama S, Suzue S, Irikura T. Structure-activity relationships of antibacterial 6,7-and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem. 1980;23(12): 1358-63.
22. Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of quinolone antibacterial agents. Yakushigaku Zasshi. 2003;38(2): 161-79.
23. Jaillon P, Morganroth J, Brumpt I, Talbot G, The Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37 Suppl A:161-7.
24. Ball AP, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety. 1999;21:407-21.
25. Breen G, Skuba K, Grasela S. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxyfluoroquinolone. J Resp Dis. 1999;20: S70-5.
26. Iannini PB, et al. Reassuring Safety Profile of Moxifloxacin. Clin Infect Dis. 2001;32(7):1112-4.
27. DupontH, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointe probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis. 1996;15(4):350-1.
28. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med. 1999;107(5): 528-9.
29. Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother. 1997;40 Suppl A: 83-92.
30. Anderson ME, Mazur A, YangT, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001;296(3):806-10.
31. Daiichi Sankyo Co, Ltd. Gracevit® tablets 50 mg, fine granules 10%: prescribing information, Japan; 2009.
32. Yamaguchi K, Ohno A, Ishii Y, Tateda K, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007. Jpn J Antibiot. 2009;62(4):346-70.
33. Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc). 2008;44(7):489-501.
34. http://www.daiichisankyo.com/news/mt_pdf/news2008_01_28_107_en.pdf Jan 28, 2008.
35. Daiichi Clinical Report, 1999 (Study PRT-015). Covance Clinical Research Unit, Leeds, UK. A randomised open label, multicentre study to compare the safety and efficacy of DU-6859a and ciprofloxacin plus metronidazole in the treatment of hospitalised patients with intra-abdominal infections.
36. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother. 2000;44:1102-7.
37. Matsumoto T, Uchino K, Yamaguchi H, Yoshida S, et al. Study on the safety and efficacy of sitafloxacin-results of the use-results survey. Jpn J Antibiot. 2011;64(5):319-37.
38. O'Grady J, Briggs A, Atarashi S, et al. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica. 2001;31(11): 811-22.
39. Ratcliffe NT, Smith JT. Ciprofloxacin and ofloxacin exhibit a rifampicinresistant bactericidal mechanism not detectable in other 4-quinolone antibacterial agents. J Pharm Pharmacol. 1984;36 Suppl:59P.
40. Ratcliffe NT, Smith JT. Norfloxacin has a novel bactericidal mechanism unrelated to that of other 4-quinolones. J Pharm Pharmacol. 1985;37 Suppl:92P.
41. Lewin CS, Smith JT. Bactericidal mechanisms of ofloxacin. J Antimicrob Chemother. 1988;22 Suppl C:1-8.
42. Lewin CS, Amyes SGB. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin. J Med Microbiol. 1989;30:227-31.
43. Lewin CS, Amyes SGB, Smith JT. Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL 16. Eur J Clin Microbiol Infect Dis. 1989;8:731-3.
44. Lewin CS, Amyes SGB. Bactericidal action of PD 127, 391, an enhanced spectrum quinolone. J Med Microbiol. 1990;33:67-70.
45. Lewin CS, Morrissey I, Smith JT. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis. J Pharm Pharmacol. 1991;43: 492-4.
46. Lewin CS, Morrissey I, Smith JT. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis. 1991;10:240-8.
47. Lewin CS. Antibacterial activity of a 1,8-naphthyridine quinolone, PD131628. J Med Microbiol. 1992;36:353-7.
48. Lewin CS, Morrissey I, Smith JT. The bactericidal activity of sparfloxacin. J Antimicrob Chemother. 1992;30:625-32.
49. Morrissey I, Smith JT. Activity of quinolone antibacterials against. Streptococcus pneumoniae. Drugs. 1993;45 Suppl 3:196-7.
50. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008;62(1):98-104.
51. Akasaka T, Kurosaka S, Uchida Y, Tanaka M, et al. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob Agents Chemother. 1998;42(5): 1284-7.
52. Morrissey I, Smith JT. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae. Drugs. 1995;49(2): 228-9.
53. Morrissey I, Smith JT. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a. J Med Microbiol. 1995;43(1):4-8.
54. Morrissey I, George J. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother. 1999;43(11):2579-85.
55. Onodera Y, Uchida Y, Tanaka M, Sato K. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother. 1999;44(4):533-6.
56. Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother. 1994;38(11):2623-7.
57. Onodera Y, Tanaka M, Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimicrob Chemother. 2001;47(4):447-50.
58. Tanaka M, Onodera Y, Uchida Y, Sato K, Hayakawa I. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother. 1997;41(11):2362-6.
59. Miyashita N, Niki Y, Matsushima T. In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrob Agents Chemother. 2001;45(11): 3270-2.
60. Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009;53:3097-9.
61. Nord CE. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis. 1996;23 Suppl 1:S15-8.
62. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 1999;43:3001-4.
63. Saito A, Tanigawara Y, Watanabe A, et al. Open study of sitafloxacin in patients with respiratory tract infections: PK/PD sutdy. Jpn J Chemother. 2008;56(1):63-80.
64. Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis. 2009;65(1):76-80.
65. Touyama M, Higa F, Nakasone C, Shinzato T, et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother. 2006;58(6):1279-82.
66. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995;39(1):170-4.
67. Sasaki J, Hori S. Oral tissue distribution, efficacy, and safety of sitofloxacin in patients with dentistry and oral surgery infection. Jpn J Chemother. 2008: 56(1):121-9.
68. Baba S, Suzuki K, Yamanaka N, et al. Efficacy and safety of sitafloxacin in patients with otorhinolaryngological infections and its tissue distribution in the otorhinolaryngological field. Jpn J Chemother. 2008;56(1):110-20.
69. Tachibana M, Tanaka M, Mitsugi K, Jin Y, Takaichi M, Okazaki O. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys. Arzneimittelforschung. 2004;54(12):898-905.
70. Payne GS, Collins DJ, Loynds P, Mould G, et al. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo 19F magnetic resonance spectroscopy. Br J Clin Pharmacol. 2005;59(2):244-8.
71. Nakashima M, Kawada Y. Pharmacokinetic profiles of sitafloxacin in renal dysfunction. Jpn J Chemother. 2008;56(1):21-4.
72. Sekino H, Kawada Y. Pharmacokinetic profiles of sitafloxacin in elderly voluteers. Jpn J Chemother. 2008;56(1):18-20.
73. Nakajima T, Okui T, Miyauchi S, et al. Effects of systemic sitafloxacin on periodontal infection control in elderly patients. Gerodontology. 2012;29(2): e1024-32.
74. Goldstein EJ. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis. 1996;23 Suppl 1:S25-30.
75. Shimoda K, Ikeda T, Okawara S, Kato M. Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice. Toxicol Sci. 2000;56(2):290-6.
76. Dawe RS, Ibbotson SH, Sanderson JB, Thomson EM, Ferguson J. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol. 2003;149(6):1232-41.
77. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents. 2001;17(3): 177-88.
78. Shetty N, Wilson AP. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2000;46(4):633-8.
79. Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother. 1998;42(7):1751-5.
80. Shiba K. Effects of ranitidine on sitofloxacin absorption. Jpn J Chemother. 2008:56(1):32-5.
81. Shiba K. Effects of metal-ion on sitofloxacin absorption. Jpn J Chemother. 2008:56(1):25-31.
82. Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother. 1995;39(7):1517-21.
83. Holden MT, Feil EJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A. 2004;101:9786-91.
84. Ghebremedhin B, König W, Witte W, Hardy KJ, Hawkey PM, König B. Subtyping of ST22-MRSA-IV (Barnim epidemic MRSA strain) at a university clinic in Germany from 2002 to 2005. J Med Microbiol. 2007;56(3): 365-75.
85. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol. 2008;8(6):747-63.
86. Collins J, Rudkin J, Recker M, Pozzi C, O'Gara JP, Massey RC. Offsetting virulence and antibiotic resistance costs by MRSA. ISME J. 2010;4: 577-84.
87. Harris SR, Feil EJ, Holden MT, et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science. 2010;327:469-74.
88. Ghebremedhin B, Olugbosi MO, Raji AM, et al. Emergence of a communityassociated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol. 2009;47(9): 2975-80.
89. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545-53.
90. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011;15(4):e277-81.
91. Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study. J Antimicrob Chemother. Jan 11, 2012. [Epub ahead of print.]
92. Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc. 2011;86(12):1230-43.
93. Forstall GJ, Knapp CC, Washington JA. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Antimicrob Agents Chemother. 1994;38(8):1868-70.
94. Cormican MG, Marshall SA, Jones RN. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). Diagn Microbiol Infect Dis. 1995;21:51-4.
95. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob. Chemother. 1997;40:639-51.
96. Cohen MA, Huband MD, Gage JG, et al. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother. 1997;40: 205-11.
97. Giamarellou-Bourboulis EJ, Sambatakou H, Grecka P, Chryssouli Z, Giamarellou H. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diag Microbiol Infect Dis. 1999;34:301-7.
98. Fuchs PC, Barry AL, Brown SD. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob Agents Chemother. 1998;42:1274-7.
99. Jones RN, Johnson DM, Biedenbach DJ, Marshall SA. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagn Microbiol Infect Dis. 1995;23:123-7.
100. Korten V, Erdem L, Murray BE. Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci. Diagn Microbiol Infect Dis. 1996;26:79-85.
101. Amano A, Matsuzaki K, Kishi N, Saika T, et al. In vitro activity of sitafloxacin against clinical isolates in 2009. Jpn J Antibiot. 2010;63(6):411-30.
102. Kanda H, Kurosaka Y, Fujikawa K, et al. In vitro and in vivo antibacterial activity of sitafloxacin. Jpn J Chemother. 2008;56(1):1-17.
103. Visalli MA, Jacobs MR, Appelbaum PC. 1996. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and-resistant pneumococci. Antimicrob Agents Chemother. 1996;40: 362-6.
104. Browne FA, Bozdogan B, Clark C, Kelly LM, et al. Antipneumococcal Activity of DK-507k, a New Quinolone, Compared with the Activities of 10 Other Agents. Antimicrob Agents Chemother. 2003;47(12): 3815-24.
105. Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. J Antimicrob Chemother. 1998;42(2):179-87.
106. Okuda J, Ramamurthy T, Yamasaki S. The potent antibacterial activity of sitafloxacin against fluoroquinolone-resistant clinical isolates of Vibrio cholerae O1. Microbiol Immunol. 2007;51(4):467-9.
107. Bale MJ, Jones RN, Erwin ME. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group. Diagn Microbiol Infect Dis. 1994;19(1): 65-8.
108. Jones RN, Barrett MS, Biedenbach DJ. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Diagn Microbiol Infect Dis. 1994;19(2): 93-9.
109. Miyachi H, Miki I, Aoyama N, Shirasaka D, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006;11(4):243-9.
110. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009;53:1720-1.
111. Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone Resistance in Helicobacter pylori: Role of Mutations at Position 87 and 91 of GyrA on the Level of Resistance and Identification of a Resistance Conferring Mutation in GyrB. Helicobacter. 2012;17(1):36-42.
112. Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative non-fermentative rods. Antimicrob Agents Chemother. 1997;41:1475-81.
113. Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995;39(7):1467-71.
114. Otani T, Tanaka M, Ito E, Kurosaka Y, et al. In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob Agents Chemother. 2003;47(12):3750-9.
115. Dhople AM, Namba K. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. Int J Antimicrob Agents. 2003;21(3):251-5.
116. Dhople AM, Namba K. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae. J Infect Chemother. 2003;9(1):12-5.
117. Dhople AM, Namba K. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. J Antimicrob Chemother. 2002;50(5):727-9.
118. Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011;37(4):296-301.
119. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother. 1994;38(12):2877-82.
120. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;36(3):682-3.
121. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents. 2000;15(2):149-52.
122. Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000;44(5):1409.
123. Hammerschlag MR. Activity of quinolones against Chlamydia pneumoniae Drugs. 1999;58 Suppl 2:78-81.
124. Roblin PM, Hammerschlag MR. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J Antimicrob Chemother. 1999;44(4):549-51.
125. Kutlin A, Roblin PM, Hammerschlag MR. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother. 2002;49(5): 763-7.
126. Terada M, Izumi K, Ohki E, Yamagishi Y, Mikamo H. Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium. J Infect Chemother. 2012;18(3):313-7.
127. Hoogkamp-Korstanje JA. In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother. 1997;40(3):427-31.
128. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis. 1996;23(Suppl 1):S2-8.
129. Kato N, Kato H, Tanaka-Bando K, Watanabe K, Ueno K. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Clin Infect Dis. 1996;23 Suppl 1: S31-5.
130. Goldstein EJ, Citron DM, Hunt Gerardo S, Hudspeth M, Merriam CV. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother. 1997;41(5): 1193-5.
131. Spangler SK, Jacobs MR, Appelbaum PC. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother. 1997;41(4):847-9.
132. Goldstein EJ, Citron DM, Warren Y, Tyrrell K, Merriam CV. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob Agents Chemother. 1999;43(9):2231-5.
133. Ackermann G, Tang YJ, Rodloff AC, Silva J Jr, Cohen SH, Heisig P. In vitro activity of sitafloxacin against Clostridium difficile. J Antimicrob Chemother. 2001;47(5):722-4.